Seres Therapeutics Reaches Analyst Target Price
September 22, 2017 at 08:36 AM EDT
In recent trading, shares of Seres Therapeutics Inc (MCRB) have crossed above the average analyst 12-month target price of $16.25, changing hands for $16.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..